| Delaware                                                             | 20-1802936                        |
|----------------------------------------------------------------------|-----------------------------------|
| (State or other jurisdiction of incorporation or organization)       | (IRS Employer Identification No.) |
|                                                                 |                              |
| 1801 South Meyers Road, Suite 220, Oakbrook Terrace, Illinois, 60181 |
| (Address of principal executive offices, Zip Code)                   |
| (630) 613-9687                                                       |
| (Issuer's telephone number including area code)                      |

| Large accelerated filer  ̈ | Accelerated filer  ̈ | Non-accelerated filer  ̈ | Smaller Reporting Company x |
|--------------------------------|--------------------------|------------------------------|-----------------------------|

----

|                                 |                                                                                                                     |   | Page  |
|--------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------|------------|
| PART I – FINANCIAL INFORMATION |                                                                                                                     |   |
|                                 |                                                                                                                     |   |       |
| Item 1.                              | Financial Statements                                                                                                     |   |       |
|                                 |                                                                                                                     |   |       |
|                                 | Condensed Consolidated Balance Sheets as of June 30, 2011 (Unaudited) and December 31, 2010                              |   | 3          |
|                                 |                                                                                                                     |   |       |
|                                 | Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2011 and 2010 |   | 4          |
|                                 |                                                                                                                     |   |       |
|                                 | Unaudited Condensed Consolidated Statements of Changes in Equity for the six months ended June 30, 2011                  |   | 5          |
|                                 |                                                                                                                     |   |       |
|                                 | Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2011 and 2010                |   | 6          |
|                                 |                                                                                                                     |   |       |
|                                 | Notes to the Unaudited Condensed Consolidated Financial Statements                                                       |   | 7          |
|                                 |                                                                                                                     |   |       |
| Item 2.                              | Management's Discussion and Analysis of Financial Conditions and Results of Operation                                    |   | 12         |
|                                 |                                                                                                                     |   |       |
| Item 3.                              | Quantitative and Qualitative Disclosure About Market Risk                                                                |   | 18         |
|                                 |                                                                                                                     |   |       |
| Item 4.                              | Controls and Procedures                                                                                                  |   | 18         |
|                                 |                                                                                                                     |   |       |
| PART II – OTHER INFORMATION    |                                                                                                                     |   |
|                                 |                                                                                                                     |   |       |
| Item 1.                              | Legal Proceedings                                                                                                        |   | 19         |
|                                 |                                                                                                                     |   |       |
| Item 1A.                             | Risk Factors                                                                                                             |   | 19         |
|                                 |                                                                                                                     |   |       |
| Item 2.                              | Unregistered Sales of Equity Securities and Use of Proceeds                                                              |   | 19         |
|                                 |                                                                                                                     |   |       |
| Item 3.                              | Defaults Upon Senior Securities                                                                                          |   | 19         |
|                                 |                                                                                                                     |   |       |
| Item 4.                              | Submission of Matters to a Vote of Security Holders                                                                      |   | 19         |
|                                 |                                                                                                                     |   |       |
| Item 5.                              | Other Information                                                                                                        |   | 19         |
|                                 |                                                                                                                     |   |       |
| Item 6.                              | Exhibits                                                                                                                 |   | 19         |
|                                 |                                                                                                                     |   |       |
| SIGNATURES                           |                                                                                                                     | 19     |
|                                 |                                                                                                                     |   |
| EXHIBIT INDEX                        |                                                                                                                     | 20     |

----

|                                                                                                    |   | June 30 |        |   | December 31 |   |
|---------------------------------------------------------------------------------------------------------|--------|--------------|-------------|--------|------------------|--------|
|                                                                                                    |   | 2011         |        |   | 2010             |   |
|                                                                                                    |   | (Unaudited)  |        |   |             |   |
| ASSETS                                                                                                  |   |         |        |   |             |   |
| Current Assets                                                                                          |   |         |        |   |             |   |
| Cash and cash equivalents                                                                               |   | $            | 65,082      |   |             | $      | 245,869 |   |
| Accounts receivable, net                                                                                |   |         | 7,641       |   |             |   | 4,165 |   |
| Receivable from sale of subsidiary                                                                      |   |         | -           |   |             |   | 39,231 |   |
| Inventories, net                                                                                        |   |         | 69,977      |   |             |   | 63,282 |   |
| Prepaid expenses and other current assets                                                               |   |         | 44,988      |   |             |   | 44,850 |   |
| Total Current Assets                                                                                    |   |         | 187,688     |   |             |   | 397,397 |   |
|                                                                                                    |   |         |        |   |             |   |   |   |
| Property and equipment, net                                                                             |   |         | 2,690,214   |   |             |   | 2,824,849 |   |
| Land use right, net                                                                                     |   |         | 344,134     |   |             |   | 347,620 |   |
|                                                                                                    |   |         |        |   |             |   |   |   |
| TOTAL ASSETS                                                                                            |   | $            | 3,222,036   |   |             | $      | 3,569,866 |   |
|                                                                                                    |   |         |        |   |             |   |   |   |
| LIABILITIES AND EQUITY                                                                                  |   |         |        |   |             |   |   |   |
| Current Liabilities                                                                                     |   |         |        |   |             |   |   |   |
| Accounts payable                                                                                        |   | $            | 74,798      |   |             | $      | 16,120 |   |
| Notes payable                                                                                           |   |         | 61,538      |   |             |   | - |   |
| Line of credit                                                                                          |   |         | 74,700      |   |             |   | - |   |
| Accrued expenses and other payables                                                                     |   |         | 126,188     |   |             |   | 64,110 |   |
| Due to director                                                                                         |   |         | 56,929      |   |             |   | 23,757 |   |
| Derivative liabilities                                                                                  |   |         | 168,087     |   |             |   | 170,551 |   |
|  Total Current Liabilities                                                                         |   |         | 562,240     |   |             |   | 274,538 |   |
|                                                                                                    |   |         |        |   |             |   |   |   |
| Commitments and contingencies                                                                           |   |         |        |   |             |   |   |   |
|                                                                                                    |   |         |        |   |             |   |   |   |
| Equity                                                                                                  |   |         |        |   |             |   |   |   |
| Common stock, $0.001 par value, 100,000,000 shares authorized, 45,070,245 shares issued and outstanding |   |         | 45,070      |   |             |   | 45,070 |   |
| Additional paid-in capital                                                                              |   |         | 19,078,722  |   |             |   | 18,987,707 |   |
| Subscription receivable                                                                                 |   |         | (210,748    | )      |             |   | (210,325 | ) |
| Stock to be issued, 1,323,000 and 900,000 shares, respectively                                          |   |         | 521,023     |   |             |   | 520,600 |   |
| Accumulated other comprehensive income                                                                  |   |         | 442,377     |   |             |   | 426,626 |   |
| Accumulated deficit                                                                                     |   |         | (17,218,388 | )      |             |   | (16,576,534 | ) |
| Total Bio-Bridge Science, Inc. Shareholders’ Equity                                          |   |         | 2,658,056   |   |             |   | 3,193,144 |   |
|                                                                                                    |   |         |        |   |             |   |   |   |
| Noncontrolling Interests                                                                                |   |         | 1,740       |   |             |   | 102,184 |   |
|                                                                                                    |   |         |        |   |             |   |   |   |
|  Total Equity                                                                                      |   |         | 2,659,796   |   |             |   | 3,295,328 |   |
|                                                                                                    |   |         |        |   |             |   |   |   |
| TOTAL LIABILITIES AND EQUITY                                                                            |   | $            | 3,222,036   |   |             | $      | 3,569,866 |   |

----

|                                                                       |   | Three Months Ended June 30 |       |   | Six Months Ended June 30 |   |
|----------------------------------------------------------------------------|--------|------------------------------------------------|------------|--------|----------------------------------------------|--------|
|                                                                       |   | 2011                                           |       |   | 2010                                         |   |   | 2011 |   |   | 2010 |   |
|                                                                       |   |                                           |       |   |                                         |   |   |   |   |   |   |   |
| Revenue                                                                    |   | $                                              | 21,207     |   |                                         | $      | 24,077 |   |   | $ | 36,340 |   |   | $ | 48,906 |   |
| Cost of goods sold                                                         |   |                                           | 12,271     |   |                                         |   | 11,955 |   |   |   | 19,958 |   |   |   | 24,086 |   |
| Gross profit                                                               |   |                                           | 8,936      |   |                                         |   | 12,122 |   |   |   | 16,382 |   |   |   | 24,820 |   |
|                                                                       |   |                                           |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Research and development costs                                             |   |                                           | 41,534     |   |                                         |   | 43,423 |   |   |   | 92,487 |   |   |   | 131,989 |   |
| Selling and distribution expenses                                          |   |                                           | 15,479     |   |                                         |   | 18,268 |   |   |   | 31,679 |   |   |   | 40,415 |   |
| General and administrative expenses                                        |   |                                           | 282,260    |   |                                         |   | 427,506 |   |   |   | 583,272 |   |   |   | 2,254,356 |   |
|                                                                       |   |                                           |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Loss from operations                                                       |   |                                           | (330,337   | )      |                                         |   | (477,075 | ) |   |   | (691,056 | ) |   |   | (2,401,940 | ) |
|                                                                       |   |                                           |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Other income (expense):                                                    |   |                                           |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Interest expense                                                           |   |                                           | -          |   |                                         |   | (2,109 | ) |   |   | (821 | ) |   |   | (2,971 | ) |
| Gain on sale trading securities                                            |   |                                           | -          |   |                                         |   | 1,890 |   |   |   | - |   |   |   | 8,631 |   |
| Change of fair value of derivative liability                               |   |                                           | 3,970      |   |                                         |   | 4,890 |   |   |   | (50,421 | ) |   |   | 4,913 |   |
| Dividend income                                                            |   |                                           | -          |   |                                         |   | 1,181 |   |   |   | - |   |   |   | 4,718 |   |
|                                                                       |   |                                           |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Loss from continuing operations                                            |   |                                           | (326,367   | )      |                                         |   | (471,223 | ) |   |   | (742,298 | ) |   |   | (2,386,649 | ) |
|                                                                       |   |                                           |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Loss from discontinued operations                                          |   |                                           | -          |   |                                         |   | (31,920 | ) |   |   | - |   |   |   | (73,041 | ) |
|                                                                       |   |                                           |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Net Loss                                                                   |   |                                           | (326,367   | )      |                                         |   | (503,143 | ) |   |   | (742,298 | ) |   |   | (2,459,690 | ) |
|                                                                       |   |                                           |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Loss from continuing operations attributable to noncontrolling interests   |   |                                           | 54,550     |   |                                         |   | 40,884 |   |   |   | 100,444 |   |   |   | 67,186 |   |
|                                                                       |   |                                           |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Loss from discontinued operations attributable to noncontrolling interests |   |                                           | -          |   |                                         |   | 21,338 |   |   |   | - |   |   |   | 34,561 |   |
|                                                                       |   |                                           |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Net loss attributable to Bio-Bridge Science, Inc.                          |   |                                           | (271,817   | )      |                                         |   | (440,921 | ) |   |   | (641,854 | ) |   |   | (2,357,943 | ) |
|                                                                       |   |                                           |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Preferred stock dividends                                                  |   |                                           | -          |   |                                         |   | - |   |   |   | - |   |   |   | (21,200 | ) |
|                                                                       |   |                                           |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Net loss attributable to common shareholders                               |   | $                                              | (271,817   | )      |                                         | $      | (440,921 | ) |   | $ | (641,854 | ) |   | $ | (2,379,143 | ) |
|                                                                       |   |                                           |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Net loss per share, attributable to common shareholders, basic and diluted |   | $                                              | (0.01      | )      |                                         | $      | (0.01 | ) |   | $ | (0.01 | ) |   | $ | (0.05 | ) |
|                                                                       |   |                                           |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Weighted average shares outstanding, basic and diluted                     |   |                                           | 45,070,245 |   |                                         |   | 45,070,245 |   |   |   | 45,070,245 |   |   |   | 44,333,203 |   |

----

|                                                                   |   | Common Stock |       |   | AdditionalPaid-in |   |   | Subscription |   |   | Stock To |   |   | AccumulatedOtherComprehensive |     |   | Accumulated |   |    | NonControlling |   |   |     |   |
|-----------------------------------------------------------------------------|--------|-------------------|------------|--------|-------------------|--------|--------|--------------|--------|--------|---------------|--------|--------|-------------------------------|----------|--------|-------------|--------|---------|----------------|--------|--------|----------|--------|
|                                                                        |   | Shares            |       |   | Amount            |   |   | Capital      |   |   | Receivable    |   |   |  Be Issued               |     |   | Income      |   |    | Deficit        |   |   | Interest |   |   | Total |   |
| BALANCEDecember 31, 2010                                               |   |              | 45,070,245 |   |              | $      | 45,070 |         |   | $      | 18,987,707    |   |   | $                             | (210,325 | )      |        | $      | 520,600 |           |   | $      | 426,626  |   |   | $ | (16,576,534 | ) |   | $ | 102,184 |   |   | $ | 3,295,328 |   |
|                                                                        |   |              |       |   |              |   |   |         |   |   |          |   |   |                          |     |   |        |   |    |           |   |   |     |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Fair value of vested options                                                |   |              | -          |   |              |   | -      |         |   |   | 38,129        |   |   |                          | -        |   |        |   | -       |           |   |   | -        |   |   |   | - |   |   |   | - |   |   |   | 38,129 |   |
|                                                                        |   |              |       |   |              |   |   |         |   |   |          |   |   |                          |     |   |        |   |    |           |   |   |     |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Extinguishment of derivative  recorded as contribution to capital |   |              | -          |   |              |   | -      |         |   |   | 52,886        |   |   |                          | -        |   |        |   | -       |           |   |   | -        |   |   |   | - |   |   |   | - |   |   |   | 52,886 |   |
|                                                                        |   |              |       |   |              |   |   |         |   |   |          |   |   |                          |     |   |        |   |    |           |   |   |     |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Exercise of 423,000 options at $0.001 per share                             |   |              | -          |   |              |   | -      |         |   |   | -             |   |   |                          | (423     | )      |        |   | 423     |           |   |   | -        |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                        |   |              |       |   |              |   |   |         |   |   |          |   |   |                          |     |   |        |   |    |           |   |   |     |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Currency translation                                                        |   |              | -          |   |              |   | -      |         |   |   | -             |   |   |                          | -        |   |        |   | -       |           |   |   | 15,751   |   |   |   | - |   |   |   | - |   |   |   | 15,751 |   |
|                                                                        |   |              |       |   |              |   |   |         |   |   |          |   |   |                          |     |   |        |   |    |           |   |   |     |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net Loss                                                                    |   |              | -          |   |              |   | -      |         |   |   | -             |   |   |                          | -        |   |        |   | -       |           |   |   | -        |   |   |   | (641,854 | ) |   |   | (100,444 | ) |   |   | (742,298 | ) |
|                                                                        |   |              |       |   |              |   |   |         |   |   |          |   |   |                          |     |   |        |   |    |           |   |   |     |   |   |   |   |   |   |   |   |   |   |   |   |   |
| BALANCEJune 30, 2011 (Unaudited)                                            |   |              | 45,070,245 |   |              | $      | 45,070 |         |   | $      | 19,078,722    |   |   | $                             | (210,748 | )      |        | $      | 521,023 |           |   | $      | 442,377  |   |   | $ | (17,218,388 | ) |   | $ | 1,740 |   |   | $ | 2,659,796 |   |

----

|                                                                        |   | Six Months Ended June 30 |     |
|-----------------------------------------------------------------------------|--------|----------------------------------------------|----------|
|                                                                        |   | 2011                                         |     |   | 2010 |   |
| CASH FLOWS FROM OPERATING ACTIVITIES                                        |   |                                         |     |   |   |   |
| Net loss                                                                    |   | $                                            | (742,298 | ) |   | $ | (2,459,690 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: |   |                                         |     |   |   |   |   |   |
| Loss from discontinued operations                                           |   |                                         | -        |   |   |   | 73,041 |   |
| Depreciation                                                                |   |                                         | 211,660  |   |   |   | 170,163 |   |
| Amortization of land use right                                              |   |                                         | 3,487    |   |   |   | 10,427 |   |
| Fair value of vested options                                                |   |                                         | 38,129   |   |   |   | 93,644 |   |
| Fair value of warrants issued to directors                                  |   |                                         | -        |   |   |   | 1,521,805 |   |
| Gain on sale of trading securities                                          |   |                                         | -        |   |   |   | (8,631 | ) |
| Change in fair value of derivative liability                                |   |                                         | 50,421   |   |   |   | (4,913 | ) |
| Change in operating assets and liabilities:                                 |   |                                         |     |   |   |   |   |   |
| Accounts receivable                                                         |   |                                         | (3,476   | ) |   |   | (15,346 | ) |
| Inventories                                                                 |   |                                         | (6,695   | ) |   |   | (59,758 | ) |
| Prepaid expense and other assets                                            |   |                                         | (138     | ) |   |   | 30,742 |   |
| Accounts payable                                                            |   |                                         | 58,678   |   |   |   | 63,095 |   |
| Accrued expenses and other payables                                         |   |                                         | 62,078   |   |   |   | 1,754 |   |
| Payable to contractors                                                      |   |                                         | -        |   |   |   | (42,471 | ) |
| Net cash used in operating activities-continuing operations                 |   |                                         | (328,154 | ) |   |   | (626,138 | ) |
| Net cash used in operating activities-discontinued operations               |   |                                         | -        |   |   |   | (112,275 | ) |
| Net cash used in operating activities                                       |   |                                         | (328,154 | ) |   |   | (738,413 | ) |
|                                                                        |   |                                         |     |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES                                        |   |                                         |     |   |   |   |   |   |
| Receivable from sale of subsidiary                                          |   |                                         | 39,231   |   |   |   | - |   |
| Purchase of property and equipment                                          |   |                                         | (5,692   | ) |   |   | (157,070 | ) |
| Payable for leasehold and equipment purchases                               |   |                                         | -        |   |   |   | (273,558 | ) |
| Proceeds from sale of trading securities                                    |   |                                         | -        |   |   |   | 170,675 |   |
| Net cash used in investing activities-continuing operations                 |   |                                         | 33,539   |   |   |   | (259,953 | ) |
| Net cash used in investing activities-discontinued operations               |   |                                         | -        |   |   |   | (4,418 | ) |
| Net cash provided by (used in) investing activities                         |   |                                         | 33,539   |   |   |   | (264,371 | ) |
|                                                                        |   |                                         |     |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES                                        |   |                                         |     |   |   |   |   |   |
| Notes payable                                                               |   |                                         | 61,538   |   |   |   | - |   |
| Line of credit                                                              |   |                                         | 74,700   |   |   |   | - |   |
| Advances from director                                                      |   |                                         | -        |   |   |   | 300,000 |   |
| Due to director                                                             |   |                                         | 33,172   |   |   |   | 5,840 |   |
| Net cash provided by financing activities                                   |   |                                         | 169,410  |   |   |   | 305,840 |   |
|                                                                        |   |                                         |     |   |   |   |   |   |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS                        |   |                                         | (125,205 | ) |   |   | (696,944 | ) |
|                                                                        |   |                                         |     |   |   |   |   |   |
| Effect of exchange rate changes on cash                                     |   |                                         | (55,582  | ) |   |   | 30,377 |   |
| Cash and cash equivalents, beginning of period                              |   |                                         | 245,869  |   |   |   | 1,481,851 |   |
|                                                                        |   |                                         |     |   |   |   |   |   |
| CASH AND CASH EQUIVALENTS, END OF PERIOD                                    |   | $                                            | 65,082   |   |   | $ | 815,284 |   |
|                                                                        |   |                                         |     |   |   |   |   |   |
| SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES               |   |                                         |     |   |   |   |   |   |
| Conversion of shares of preferred stock into shares of common stock         |   | $                                            | -        |   |   | $ | 4,000 |   |
| Extinguishment of derivative recorded as contribution to capital            |   | $                                            | 52,886   |   |   | $ | 176,032 |   |
| Accrual of preferred stock dividend payable in common stock                 |   | $                                            | -        |   |   | $ | 21,200 |   |
| Payment of preferred stock dividend in shares of common stock               |   | $                                            | -        |   |   | $ | 95,400 |   |

----

----

|                               |   | Level 1 |   |   | Level 2 |   |   | Level 3 |   |   | Total   |   |
|------------------------------------|--------|--------------|--------|--------|--------------|--------|--------|--------------|--------|--------|---------|--------|
| Fair value of options and warrants |   | $            | -      |   |         | $      | -      |         |   | $      | 168,087 |   |   | $ | 168,087 |   |
|                               |   | $            | -      |   |         | $      | -      |         |   | $      | 168,087 |   |   | $ | 168,087 |   |

----

|                               |   | Level 1 |   |   | Level 2 |   |   | Level 3 |   |   | Total   |   |
|------------------------------------|--------|--------------|--------|--------|--------------|--------|--------|--------------|--------|--------|---------|--------|
| Fair value of options and warrants |   | $            | -      |   |         | $      | -      |         |   | $      | 170,551 |   |   | $ | 170,551 |   |
|                               |   | $            | -      |   |         | $      | -      |         |   | $      | 170,551 |   |   | $ | 170,551 |   |

|                                                               |   | 2011   |   |   | 2010   |   |
|--------------------------------------------------------------------|--------|--------|--------|--------|--------|--------|
| US$ to RMB exchange rate on January 1,                             |   |   | 6.6227 |   |   |   | 6.8282 |   |
|                                                               |   |   |   |   |   |   |   |   |
| US$ to RMB exchange rate on June 30,                               |   |   | 6.5000 |   |   |   | 6.7909 |   |
|                                                               |   |   |   |   |   |   |   |   |
| Average US$ to RMB exchange rate for the six months ended June 30, |   |   | 6.5614 |   |   |   | 6.8251 |   |

|                                              | Three months ended June 30 |     | Six months ended June 30 |   |
|---------------------------------------------------|------------------------------------------------|----------|----------------------------------------------|--------|
|                                              | 2011                                           |     | 2010                                         |   | 2011 |   | 2010 |   |
| Net loss attributable to Bio-Bridge Science, Inc. | $                                              | (271,817 | )                                            | $      | (440,921 | ) | $ | (641,854 | ) | $ | (2,357,943 | ) |
| Foreign currency translation gain                 |                                           | 27,024   |                                         |   | 28,791 |   |   | 15,751 |   |   | 30,377 |   |
| Comprehensive loss                                | $                                              | (244,793 | )                                            | $      | (412,130 | ) | $ | (626,103 | ) | $ | (2,327,566 | ) |

----

|                                                                     |   | 3 Months EndedJune 30, 2010 |    |   | 6 Months EndedJune 30, 2010 |   |
|--------------------------------------------------------------------------|--------|-------------------------------------------------|---------|--------|-------------------------------------------------|--------|
| Revenue                                                                  |   | $                                               | 122,429 |   |                                            | $      | 157,965 |   |
|                                                                     |   |                                            |    |   |                                            |   |   |   |
| Loss from discontinued operations                                        |   |                                            | (31,920 | )      |                                            |   | (73,041 | ) |
| Loss attributable to noncontrolling interests                            |   |                                            | 21,338  |   |                                            |   | 34,561 |   |
| Loss from discontinued operations applicable to Bio-Bridge Science, Inc. |   | $                                               | (10,582 | )      |                                            | $      | (38,480 | ) |
|                                                                     |   |                                            |    |   |                                            |   |   |   |
| Loss per share from discontinued operations – Basic and Diluted    |   | $                                               | (0.00   | )      |                                            | $      | (0.00 | ) |

|              |   | June 30, 2011 |    |   | December 31, 2010 |   |
|-------------------|--------|-------------------------|---------|--------|-----------------------------|--------|
|              |   | (Unaudited)             |    |   |                        |   |
| Raw materials     |   | $                       | 25,313  |   |                        | $      | 18,207 |   |
| Finished goods    |   |                    | 91,664  |   |                        |   | 92,075 |   |
| Inventory reserve |   |                    | (47,000 | )      |                        |   | (47,000 | ) |
| Inventories, net  |   | $                       | 69,977  |   |                        | $      | 63,282 |   |

----

|                                     |   | Number ofOptions |      |   | Weighted AverageExercise Price |   |
|------------------------------------------|--------|-----------------------|-----------|--------|------------------------------------------|--------|
| Outstanding at December 31, 2010         |   |                  | 3,082,000 |   |                                     | $      | 0.37 |   |
|                                     |   |                  |      |   |                                     |   |   |   |
| Granted                                  |   |                  | -         |   |                                     | $      | - |   |
| Exercised                                |   |                  | (423,000  | )      |                                     | $      | 0.001 |   |
| Forfeited                                |   |                  | -         |   |                                     | $      | - |   |
|                                     |   |                  |      |   |                                     |   |   |   |
| Outstanding at June 30, 2011 (unaudited) |   |                  | 2,659,000 |   |                                     | $      | 0.43 |   |

| Options Outstanding          |                     |   | Options Exercisable |   |
|-----------------------------------|--------------------------|--------|--------------------------|--------|
| Range of ExercisePrices |                     |   | Number ofShares     |   |   | Weighted AverageExercise Price |   |   | Weighted AverageRemaining Life (years) |   |   | Number ofShares |   |   | Weighted AverageExercise Price |   |
| $                                 | 0.001 to $0.55 |   |                     |   | 2,659,000 |   |   | $ | 0.43 |   |   | 5.54 |   |   |   | 2,598,750 |   |   | $ | 0.43 |   |

| Exercise price |        |   | Number ofShares Outstanding |   |      | Remaininglife (years) |   |         | Number ofShares Exercisable |   |   | Weighted averageexercise price |   |
|---------------------|-------------|--------|---------------------------------------|--------|-----------|----------------------------|--------|--------------|---------------------------------------|--------|--------|------------------------------------------|--------|
| $                   | 0.001       |   |                                  |   | 400,000   |                       |   | 4.83         |                                  |   |   | 400,000                                  |   |   | $ | 0.00 |   |
| $                   | 0.47        |   |                                  |   | 390,000   |                       |   | 8.30         |                                  |   |   | 371,250                                  |   |   | $ | 0.07 |   |
| $                   | 0.50        |   |                                  |   | 897,000   |                       |   | 4.75         |                                  |   |   | 897,000                                  |   |   | $ | 0.17 |   |
| $                   | 0.52        |   |                                  |   | 240,000   |                       |   | 8.30         |                                  |   |   | 190,000                                  |   |   | $ | 0.04 |   |
| $                   | 0.55        |   |                                  |   | 600,000   |                       |   | 4.83         |                                  |   |   | 600,000                                  |   |   | $ | 0.13 |   |
| $                   | 0.50        |   |                                  |   | 132,000   |                       |   | 8.75         |                                  |   |   | 115,500                                  |   |   | $ | 0.02 |   |
| $                   | 0.001to0.55 |   |                                  |   | 2,659,000 |                       |   | 4.83 to 8.75 |                                  |   |   | 2,598,750                                |   |   | $ | 0.43 |   |

|                                                  |   | Number of SharesUnder Warrants |      |   | Weighted AverageExercise Price |   |
|-------------------------------------------------------|--------|-----------------------------------------------|-----------|--------|------------------------------------------|--------|
| Warrants outstanding at December 31, 2010             |   |                                          | 9,414,942 |   |                                     | $      | 0.94 |   |
| Warrants granted                                      |   |                                          | -         |   |                                     | $      | - |   |
| Warrants expired                                      |   |                                          | (163,333  | )      |                                     | $      | 0.75 |   |
| Warrants outstanding and exercisable at June 30, 2011 |   |                                          | 9,251,609 |   |                                     | $      | 0.94 |   |

| Warrants Outstanding and Exercisable |      |
|-----------------------------------------------------|-----------|
| Number of Shares Under Warrants |      |   | Exercise Price |   | Expiration Date |   | Weighted AverageExercise Price |   |
|                                                | 20,000    |   |   | $ | 0.75 |   | June 4, 2012 |   | $ | 0.00 |   |
|                                                | 183,333   |   |   | $ | 1.20 |   | June 4, 2013 |   | $ | 0.02 |   |
|                                                | 1,724,138 |   |   | $ | 0.725 |   | July 2, 2012 |   | $ | 0.14 |   |
|                                                | 1,724,138 |   |   | $ | 1.10 |   | July 2, 2013 |   | $ | 0.20 |   |
|                                                | 1,000,000 |   |   | $ | 0.725 |   | July 9, 2012 |   | $ | 0.08 |   |
|                                                | 1,000,000 |   |   | $ | 1.10 |   | July 9, 2013 |   | $ | 0.12 |   |
|                                                | 3,000,000 |   |   | $ | 1.00 |   | January 20, 2015 |   | $ | 0.32 |   |
|                                                | 300,000   |   |   | $ | 0.725 |   | December 15, 2014 |   | $ | 0.02 |   |
|                                                | 300,000   |   |   | $ | 1.00 |   | December 15, 2015 |   | $ | 0.04 |   |
|                                                | 9,251,609 |   |   | $ | 0.75 to 1.20 |   |   |   | $ | 0.94 |   |

----

|                     |   | June 30, 2011(unaudited) |    |   | December 31, 2010 |   |
|--------------------------|--------|------------------------------------|---------|--------|-----------------------------|--------|
| Risk-free interest rate  |   |                               | 0.19    | %      |                        |   | 0.27 | % |
| Expected volatility      |   |                               | 188.2   | %      |                        |   | 202.3 | % |
| Expected life (in years) |   | 0.75 to 1.93                       |    |   | 0.4 to 2.4 years            |   |
| Expected dividend yield  |   |                               | 0.00    | %      |                        |   | 0.00 | % |
|                     |   |                               |    |   |                        |   |   |   |
| Fair Value:              |   |                               |    |   |                        |   |   |   |
| Options and warrants     |   | $                                  | 168,087 |   |                        | $      | 170,551 |   |

----

|   | · | our ability to finance our activities and maintain our financial liquidity; |
|--------|--------|-----------------------------------------------------------------------------|

|   | · | our ability to attract and retain qualified, knowledgeable employees; |
|--------|--------|-----------------------------------------------------------------------|

|   | · | our ability to complete product development; |
|--------|--------|----------------------------------------------|

|   | · | our ability to obtain regulatory approvals to conduct clinical trials; |
|--------|--------|------------------------------------------------------------------------|

|   | · | our ability to design and market new products successfully; |
|--------|--------|-------------------------------------------------------------|

|   | · | our ability to acquire new customers in the future; |
|--------|--------|-----------------------------------------------------|

|   | · | deterioration of business and economic conditions in our markets; and |
|--------|--------|-----------------------------------------------------------------------|

|   | · | intensely competitive industry conditions. |
|--------|--------|--------------------------------------------|

----

|   | · | approximately $1.2 million for preparatory work and Phase I clinical study of HIV-PV Vaccine I; |
|--------|--------|-------------------------------------------------------------------------------------------------|

|   | · | approximately $ 1 million for working capital and general corporate needs; and |
|--------|--------|--------------------------------------------------------------------------------|

|   | · | approximately $1.5 million for production of colon cancer vaccine and HPV vaccine and their pre-clinical trials |
|--------|--------|-----------------------------------------------------------------------------------------------------------------|

----

----

----

----

----

| /s/  Dr. Liang Qiao                                                     |
|------------------------------------------------------------------------------|
| By: Dr. Liang Qiao Chief Executive Officer(Principal Executive Officer) |

----

| 3.1(i)*    |   | Certificate of incorporation of the registrant, as currently in effect                                                                                                             |
|------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       |   |                                                                                                                                                                               |
| 3.1(ii)*   |   | Bylaws of the registrant, as currently in effect                                                                                                                                   |
|       |   |                                                                                                                                                                               |
| 3.1(iii)** |   | Certificate of Designation of Series A Preferred Stock                                                                                                                             |
|       |   |                                                                                                                                                                               |
| 31.1       |   | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                                                             |
|       |   |                                                                                                                                                                               |
| 31.2       |   | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                                                             |
|       |   |                                                                                                                                                                               |
| 32         |   | Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002 |

----